Please login to the form below

Not currently logged in
Email:
Password:

Allergan builds on gene editing deal

Firm will co-develop CRISPR candidate for vision-threatening disorder

AllerganAllergan has taken up the option of developing and marketing a CRISPR candidate from Editas to treat a retinal degenerative disorder.

Building on its existing licensing options deal with the genome editing company Allergan has now confirmed it will co-develop and co-commercialise EDIT-101, which is part of the terms of the $90m deal.

That existing deal gives Allergan exclusive access, along with the option to license up to five of Editas’ genome editing programmes for ocular disease, including EDIT-101.

In conjunction with its option to co-develop and co-commercialise, Editas received $15m for EDIT-101, and is eligible for an additional $25m upon acceptance of an investigational new drug application by the FDA.

If all goes well, the companies are hoping that EDIT-101 will soon treat patients suffering with an eye condition called Leber Congenital Amaurosis 10 (LCA10), a disorder caused by mutations to a single gene.

It is the most common form of LCA, which is the most common cause of inherited childhood blindness, occurring in every 2-3 per 100,000 live births worldwide.

CRISPR-based medicines have the potential to be game-changers for patients with both genetically-defined and genetically-treatable diseases of the eye," said David Nicholson, Ph.D., chief research and development officer, Allergan. "The Allergan team is excited to work with colleagues at Editas Medicine to develop EDIT-101 and potentially deliver a transformative medicine for LCA10 patients."

Katrine Bosley

"Today marks a significant milestone in our collaboration with Allergan and in our work to develop genomic medicines to treat eye diseases," said Katrine Bosley, president and chief executive officer, Editas Medicine. "Allergan is a long-time innovator in ophthalmology, and their deep experience in developing, manufacturing, and commercialising medicines globally will meaningfully advance the EDIT-101 programme and maximise our ability to bring this transformative medicine to people living with LCA10."

CRISPR, is a technology that can edit DNA at precise locations in the human genome, allowing researchers to permanently modify genes.

The technology has attracted huge interest and investment over the last few years, but recent news has knocked confidence in the approach.

Back in March, the US regulator halted Vertex Pharma’s planned trial involving CRISPR for sickle cell disease, which will likely delay the use of CRISPR-based therapies in humans.

Meanwhile a paper published in the journal Nature Biotechnology found the technique can cause unexpected genetic damage which could lead to dangerous changes in some cells.

This added to separate research which suggested the CRISPR gene editing might inadvertently increase cancer risk in some cells. These developments have caused the shares of leaders in the field, CRISPR Therapeutics, Intellia Therapeutics and Editas, to drop sharply.

However, Editas CEO Katrine Bosley remains optimistic, and her company's partnership with Allergan will be one of the first tests of the long-term viability of the technology.

Article by
Gemma Jones

7th August 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics